Quick Summary
- ARK Invest acquired 112,815 shares of CRISPR Therapeutics totaling approximately $5.63M through ARKK and ARKG ETFs
- The firm purchased 275,000 shares of PayPay Corp worth roughly $4.4M via its ARKF fintech ETF
- Additional purchases included GeneDx (approximately $4.43M) and Tempus AI (around $991K)
- ARK reduced its holdings in Teradyne (roughly $3.3M) and Ionis Pharmaceuticals (about $3.26M)
- The firm also decreased exposure to 10x Genomics and Circle Internet Group
Cathie Wood’s ARK Invest executed more than $10 million worth of stock purchases on March 12, 2026, while simultaneously trimming multiple existing holdings, based on the firm’s publicly disclosed daily trading activity.
The most substantial acquisition was in CRISPR Therapeutics. ARK accumulated 112,815 shares distributed across two exchange-traded funds — the ARK Innovation ETF and the ARK Genomic Revolution ETF — representing a combined investment of approximately $5.63 million.
CRISPR Therapeutics specializes in gene-editing biotechnology. This acquisition reinforces ARK’s ongoing conviction in the transformative potential of genomic medicine technologies.
The second-largest purchase involved PayPay Corp, a digital payments provider. ARK accumulated 275,000 shares via its ARK Fintech Innovation ETF, representing an investment of approximately $4.4 million.
PayPay Corp experienced a significant 13.50% gain during trading. This transaction strengthens ARK’s commitment to the fintech sector and digital payment infrastructure.
ARK expanded positions in two additional companies as well. The firm acquired 52,075 shares of GeneDx, which operates in genomic diagnostics, valued at approximately $4.43 million. Additionally, it purchased 18,820 shares of Tempus AI, an artificial intelligence-driven healthcare data platform, for around $991,000.
ARK’s Portfolio Reductions
Regarding sales, ARK divested 10,919 shares of Teradyne, which manufactures chip-testing equipment, through the ARK Innovation ETF for approximately $3.3 million. Teradyne experienced a 5.09% decline that trading session.
This divestment represents a continuation of recent activity. ARK has been systematically reducing its Teradyne exposure across multiple trading sessions.
ARK additionally sold 43,533 shares of Ionis Pharmaceuticals via its ARKG ETF, valued at roughly $3.26 million. Ionis shares declined 3.28% during the session.
The Ionis divestment reflects an ongoing pattern of ARK decreasing its stake in the RNA-based pharmaceutical developer.
ARK reduced two additional holdings as well. The firm sold 18,392 shares of 10x Genomics, which develops gene expression technologies, for approximately $376,000 across ARKK and ARKG.
Additionally, it divested 11,194 shares of Circle Internet Group, a stablecoin and blockchain payment infrastructure company, through ARKK for roughly $1.26 million.
Analyst Perspectives
Wall Street analysts currently assign “Strong Buy” ratings to both GeneDx and Ionis Pharmaceuticals. GeneDx commands the most significant upside potential among the group, approaching 100%.
CRISPR Therapeutics, Tempus AI, Teradyne, and 10x Genomics each carry “Moderate Buy” ratings from the analyst community. PayPay Corp receives a “Hold” rating.
ARK executed an additional smaller transaction, acquiring 54,736 shares of Canton Strategic Holdings through its ARKF ETF, worth approximately $254,522.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
